Barclays analyst Matt Miksic raised the firm’s price target on Edwards Lifesciences (EW) to $88 from $85 and keeps an Overweight rating on the shares. The firm expects the company’s investor day to be a positive catalyst. It believes managemewbt will provide a positive 2025 outlook, in line with Street expectations of 7%-9% organic sales growth and earnings per share in the range of $2.40 – 2.50, adjusting for the divestiture of Critical Care.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $80 from $75 at RBC Capital
- Edwards Lifesciences announces presentation of one-year SAPIEN 3 data
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Edwards Lifesciences call volume above normal and directionally bullish
- Edwards Lifesciences Evoque demonstrated superiority vs. medical therapy alone